Skip to main content
. 2021 Dec 14;11:564234. doi: 10.3389/fonc.2021.564234

Table 3.

Base case results of the cost-effectiveness analysis.

Treatment Cost (CNY) QALYs Incremental Cost (CNY) Incremental QALYs ICER
Dacomitinib 265,512 1.9548
Gefitinib 247,048 1.6067 18,463 0.3132 58,947

CNY, Chinese Yuan; QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio.